Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxycodone immediate release - Purdue

Drug Profile

Oxycodone immediate release - Purdue

Alternative Names: OxiFast; OxiNorm; OxyFast; OxyGesic; OxyIR; OxylR; OxyNorm; S-8116; S-8117; S-811717

Latest Information Update: 11 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Purdue Pharma
  • Developer Mundipharma International; Napp Pharmaceutical Group; Purdue Pharma; Shionogi
  • Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain; Pain
  • Phase III Back pain; Postoperative pain

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 05 Jun 2018 Phase III clinical trials for Pain in Japan (PO) (JapicCTI-183986)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pain in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top